Company news

4D Molecular Therapeutics, Inc. news in 2024

4D Molecular Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

December 15, 2024

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

November 13, 2024

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

November 12, 2024

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

September 22, 2024

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

September 17, 2024

4DMT Announces Presentations at Upcoming Retina Conferences

September 4, 2024

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

September 2, 2024

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

August 26, 2024

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

August 11, 2024

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

August 7, 2024

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

August 4, 2024

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

July 16, 2024

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

June 23, 2024

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

June 17, 2024

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

June 7, 2024

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

June 5, 2024

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

June 3, 2024

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

May 29, 2024

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

May 8, 2024

4DMT to Participate in Upcoming Investor Conference

May 6, 2024

4DMT Announces Presentations at ARVO 2024 Annual Meeting

April 30, 2024

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

March 27, 2024

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

February 28, 2024

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

February 11, 2024

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

February 5, 2024

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

February 4, 2024

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

February 2, 2024

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

January 28, 2024

4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease

January 22, 2024

4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

January 3, 2024

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

January 2, 2024

Decks in 2024